{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:42:54Z","timestamp":1791222174111,"version":"4.1.0"},"reference-count":118,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1038\/ctg.2015.33","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T10:40:44Z","timestamp":1440672044000},"page":"e109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis"],"prefix":"10.14309","volume":"6","author":[{"given":"Seth N","family":"Sclair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210317","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-014-8456-5","article-title":"New therapies for primary biliary cirrhosis.","volume":"48","author":"Floreani","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"R2-4-20210317","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MOG.0000000000000058","article-title":"Primary biliary cirrhosis in 2014.","volume":"30","author":"Flores","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"key":"R3-4-20210317","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","article-title":"Primary biliary cirrhosis.","volume":"377","author":"Selmi","year":"2011","journal-title":"Lancet"},{"key":"R4-4-20210317","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cld.2012.12.003","article-title":"Primary biliary cirrhosis: therapeutic advances.","volume":"17","author":"Czul","year":"2013","journal-title":"Clin Liver Dis"},{"key":"R5-4-20210317","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review.","volume":"56","author":"Boonstra","year":"2012","journal-title":"J Hepatol"},{"key":"R6-4-20210317","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years.","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"key":"R7-4-20210317","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.cgh.2007.07.015","article-title":"Transplantation trends in primary biliary cirrhosis.","volume":"5","author":"Lee","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R9-4-20210317","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid.","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"R10-4-20210317","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and longterm prognosis in primary biliary cirrhosis.","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"R11-4-20210317","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"R12-4-20210317","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis.","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R13-4-20210317","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"R14-4-20210317","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"R15-4-20210317","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.","volume":"36","author":"Paumgartner","year":"2002","journal-title":"Hepatology"},{"key":"R16-4-20210317","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S2210-7401(12)70015-3","article-title":"Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.","volume":"36","author":"Poupon","year":"2012","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R17-4-20210317","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis.","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"R18-4-20210317","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1572-0241.2004.04047.x","article-title":"Prolonged follow-up of patients in the US multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis.","volume":"99","author":"Combes","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R19-4-20210317","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.","volume":"57","author":"Honda","year":"2013","journal-title":"Hepatology"},{"key":"R20-4-20210317","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to to ursodeoxycholic acid.","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-4-20210317","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","article-title":"Bezafibrate normalizes alkaline phospatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid.","volume":"34","author":"Lens","year":"2014","journal-title":"Liver Int"},{"key":"R22-4-20210317","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ajg.2015.20","article-title":"A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.","volume":"110","author":"Hosonuma","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R23-4-20210317","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clinre.2015.02.011","article-title":"Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: a meta-analysis.","volume":"39","author":"Grigorian","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R24-4-20210317","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"key":"R25-4-20210317","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a threeyear randomized trial.","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"key":"R26-4-20210317","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.","volume":"31","author":"Angulo","year":"2000","journal-title":"Hepatology"},{"key":"R27-4-20210317","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in earlyand latestage primary biliary cirrhosis.","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"key":"R28-4-20210317","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.","volume":"148","author":"Hirschfield","year":"2014","journal-title":"Gastroenterology"},{"key":"R31-4-20210317","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/hep.21151","article-title":"Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC.","volume":"43","author":"Corpechot","year":"2006","journal-title":"Hepatology"},{"key":"R32-4-20210317","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastographybased assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis.","volume":"56","author":"Corpechot","year":"2012","journal-title":"Hepatology"},{"key":"R33-4-20210317","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cgh.2014.04.039","article-title":"FibroScan (vibration-controlled transient elastography): where does it stand in the united states practice.","volume":"13","author":"Tapper","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R34-4-20210317","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/hep.21907","article-title":"Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis.","volume":"46","author":"GarciaTsao","year":"2007","journal-title":"Hepatology"},{"key":"R35-4-20210317","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/0016-5085(89)90526-X","article-title":"Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival.","volume":"96","author":"Gores","year":"1989","journal-title":"Gastroenterology"},{"key":"R36-4-20210317","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cgh.2007.02.031","article-title":"Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis.","volume":"5","author":"Levy","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R38-4-20210317","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cgh.2006.09.031","article-title":"Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis.","volume":"5","author":"Suzuki","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R39-4-20210317","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/hep.23095","article-title":"Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers.","volume":"50","author":"Cavazza","year":"2009","journal-title":"Hepatology"},{"key":"R40-4-20210317","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/hep.26176","article-title":"Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan.","volume":"57","author":"Harada","year":"2013","journal-title":"Hepatology"},{"key":"R41-4-20210317","first-page":"1495","article-title":"Adang RP et alStudy Group. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid.","volume":"22","author":"Kuiper","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R42-4-20210317","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0016-5085(80)90131-6","article-title":"Clinicopathologic features of the syndrome of primary sclerosing cholangitis.","volume":"79","author":"Wiesner","year":"1980","journal-title":"Gastroenterology"},{"key":"R43-4-20210317","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3109\/00365528009181516","article-title":"Sclerosing cholangitis in ulcerative colitis.","volume":"15","author":"Schrumpf","year":"1980","journal-title":"Scand J Gastroenterol"},{"key":"R44-4-20210317","first-page":"503","article-title":"Ulcerative colitis and persistent liver dysfunction.","volume":"52","author":"Shepherd","year":"1983","journal-title":"Q J Med"},{"key":"R45-4-20210317","first-page":"229","article-title":"Primary sclerosing cholangitis associated with inflammatory bowel disease in cape town, 1975 - 1981.","volume":"63","author":"Tobias","year":"1983","journal-title":"S Afr Med J"},{"key":"R46-4-20210317","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/hep.1840100406","article-title":"Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis.","volume":"10","author":"Wiesner","year":"1989","journal-title":"Hepatology"},{"key":"R47-4-20210317","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/0016-5085(91)70019-T","article-title":"Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis.","volume":"100","author":"Olsson","year":"1991","journal-title":"Gastroenterology"},{"key":"R48-4-20210317","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0168-8278(94)80240-8","article-title":"Epidemiology of primary sclerosing cholangitis in Spain.","volume":"21","author":"Escorsell","year":"1994","journal-title":"J Hepatol"},{"key":"R49-4-20210317","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJM199504063321406","article-title":"Primary sclerosing cholangitis.","volume":"332","author":"Lee","year":"1995","journal-title":"N Engl J Med"},{"key":"R50-4-20210317","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/gut.38.4.610","article-title":"Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.","volume":"38","author":"Broome","year":"1996","journal-title":"Gut"},{"key":"R51-4-20210317","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","article-title":"The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.","volume":"96","author":"Bernstein","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R52-4-20210317","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.gastro.2003.07.011","article-title":"Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a united states community.","volume":"125","author":"Bambha","year":"2003","journal-title":"Gastroenterology"},{"key":"R53-4-20210317","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1053\/j.gastro.2004.04.052","article-title":"Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom.","volume":"126","author":"Kingham","year":"2004","journal-title":"Gastroenterology"},{"key":"R54-4-20210317","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-2006-933560","article-title":"Primary sclerosing cholangitis: epidemiology, natural history, and prognosis.","volume":"26","author":"Levy","year":"2006","journal-title":"Semin Liver Dis"},{"key":"R55-4-20210317","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/hep.24247","article-title":"Incidence of primary sclerosing cholangitis: a systematic review and metaanalysis.","volume":"53","author":"Molodecky","year":"2011","journal-title":"Hepatology"},{"key":"R56-4-20210317","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","article-title":"Primary sclerosing cholangitis.","volume":"382","author":"Hirschfield","year":"2013","journal-title":"Lancet"},{"key":"R57-4-20210317","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2003.11.009","article-title":"Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of intercellular adhesion molecule-1.","volume":"40","author":"Yang","year":"2004","journal-title":"J Hepatol"},{"key":"R58-4-20210317","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cgh.2008.03.016","article-title":"Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis.","volume":"6","author":"Bergquist","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R59-4-20210317","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2009.11.046","article-title":"Genome-wide association analysis in primary sclerosing cholangitis.","volume":"138","author":"Karlsen","year":"2010","journal-title":"Gastroenterology"},{"key":"R60-4-20210317","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/ng.2616","article-title":"Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis.","volume":"45","author":"Liu","year":"2013","journal-title":"Nat Genet"},{"key":"R61-4-20210317","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1053\/j.gastro.2013.03.053","article-title":"The genetics of complex cholestatic disorders.","volume":"144","author":"Hirschfield","year":"2013","journal-title":"Gastroenterology"},{"key":"R62-4-20210317","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/bmb\/ldu008","article-title":"Advances and controversies in the pathogenesis and management of primary sclerosing cholangitis.","volume":"110","author":"Eksteen","year":"2014","journal-title":"Br Med Bull"},{"key":"R63-4-20210317","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3109\/00365521.2014.913189","article-title":"Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies.","volume":"49","author":"Tabibian","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"R64-4-20210317","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5582\/irdr.2014.01018","article-title":"Current research on the treatment of primary sclerosing cholangitis.","volume":"4","author":"Ali","year":"2014","journal-title":"Intractable Rare Dis Res"},{"key":"R65-4-20210317","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1572-0241.2006.00872.x","article-title":"Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study.","volume":"102","author":"Tischendorf","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R66-4-20210317","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.3748\/wjg.14.3338","article-title":"Clinical features and management of primary sclerosing cholangitis.","volume":"14","author":"Silveira","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R67-4-20210317","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis.","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"key":"R68-4-20210317","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.autrev.2014.01.040","article-title":"Diagnosis and classification of primary sclerosing cholangitis.","volume":"13","author":"Yimam","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R69-4-20210317","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0168-8278(00)80061-6","article-title":"Serum autoantibodies in patients with primary sclerosing cholangitis.","volume":"32","author":"Angulo","year":"2000","journal-title":"J Hepatol"},{"key":"R70-4-20210317","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL clinical practice guidelines: management of cholestatic liver diseases.","volume":"51","year":"2009","journal-title":"J Hepatol"},{"key":"R71-4-20210317","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2559.2011.03853.x","article-title":"Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation.","volume":"60","author":"Portmann","year":"2012","journal-title":"Histopathology"},{"key":"R72-4-20210317","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1053\/jhep.2002.33202","article-title":"Smallduct primary sclerosing cholangitis: a longterm followup study.","volume":"35","author":"Angulo","year":"2002","journal-title":"Hepatology"},{"key":"R73-4-20210317","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/gut.51.5.731","article-title":"Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis.","volume":"51","author":"Bjornsson","year":"2002","journal-title":"Gut"},{"key":"R74-4-20210317","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0168-8278(02)00036-3","article-title":"Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC).","volume":"36","author":"Broome","year":"2002","journal-title":"J Hepatol"},{"key":"R75-4-20210317","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1572-0241.2007.01103.x","article-title":"The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis.","volume":"102","author":"Kaplan","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R76-4-20210317","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/j.gastro.2008.01.042","article-title":"The natural history of small-duct primary sclerosing cholangitis.","volume":"134","author":"Bjornsson","year":"2008","journal-title":"Gastroenterology"},{"key":"R77-4-20210317","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s12072-011-9260-4","article-title":"Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature.","volume":"5","author":"Singal","year":"2011","journal-title":"Hepatol Int"},{"key":"R78-4-20210317","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MCG.0b013e318157c614","article-title":"Characteristics and long-term prognosis of the autoimmune hepatitisprimary sclerosing cholangitis overlap syndrome.","volume":"43","author":"Luth","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"R79-4-20210317","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/MJT.0b013e3181c9dac6","article-title":"Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy.","volume":"18","author":"Bjornsson","year":"2011","journal-title":"Am J Ther"},{"key":"R80-4-20210317","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/j.1572-0241.2006.00772.x","article-title":"Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis.","volume":"101","author":"Mendes","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R81-4-20210317","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2007.12.009","article-title":"Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy.","volume":"134","author":"Ghazale","year":"2008","journal-title":"Gastroenterology"},{"key":"R82-4-20210317","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cld.2012.11.007","article-title":"IgG4-associated cholangitis.","volume":"17","author":"Silveira","year":"2013","journal-title":"Clin Liver Dis"},{"key":"R83-4-20210317","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.autrev.2014.08.013","article-title":"The clinical spectrum of IgG4-related disease.","volume":"13","author":"Brito-Zeron","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R84-4-20210317","first-page":"49","article-title":"An update on primary sclerosing cholangitis: from pathogenesis to treatment.","volume":"59","author":"Imam","year":"2013","journal-title":"Minerva Gastroenterol Dietol"},{"key":"R85-4-20210317","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s10067-013-2326-z","article-title":"The great mimicker: IgG4-related disease.","volume":"32","author":"Alamino","year":"2013","journal-title":"Clin Rheumatol"},{"key":"R86-4-20210317","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/hep.26977","article-title":"Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4associated cholangitis from primary sclerosing cholangitis.","volume":"59","author":"Boonstra","year":"2014","journal-title":"Hepatology"},{"key":"R87-4-20210317","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2012.10.013","article-title":"Improvement of serum alkaline phosphatase to 1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis.","volume":"58","author":"Al Mamari","year":"2013","journal-title":"J Hepatol"},{"key":"R88-4-20210317","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","article-title":"Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.","volume":"11","author":"Lindstrom","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R89-4-20210317","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/apt.12979","article-title":"Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis.","volume":"40","author":"Rupp","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R90-4-20210317","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/hep.22789","article-title":"Bile acids: trying to understand their chemistry and biology with the hope of helping patients.","volume":"49","author":"Hofmann","year":"2009","journal-title":"Hepatology"},{"key":"R91-4-20210317","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis.","volume":"336","author":"Lindor","year":"1997","journal-title":"N Engl J Med"},{"key":"R92-4-20210317","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterology"},{"key":"R93-4-20210317","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"Highdose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"R94-4-20210317","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.27074","article-title":"Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.","volume":"60","author":"Wunsch","year":"2014","journal-title":"Hepatology"},{"key":"R95-4-20210317","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/hep.27180","article-title":"Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?).","volume":"60","author":"Tabibian","year":"2014","journal-title":"Hepatology"},{"key":"R97-4-20210317","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitisa pilot study.","volume":"37","author":"Tabibian","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R98-4-20210317","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MPG.0b013e31816fee95","article-title":"Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic.","volume":"47","author":"Davies","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R99-4-20210317","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10875-012-9801-1","article-title":"Immunomodulatory effect of vancomycin on treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis.","volume":"33","author":"Abarbanel","year":"2013","journal-title":"J Clin Immunol"},{"key":"R102-4-20210317","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2036.2011.04926.x","article-title":"The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis-a pilot study.","volume":"35","author":"Martin","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R104-4-20210317","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1572-0241.2004.04106.x","article-title":"Dominant strictures in patients with primary sclerosing cholangitis.","volume":"99","author":"Bjornsson","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R105-4-20210317","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jhep.2009.01.023","article-title":"Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis.","volume":"51","author":"Rudolph","year":"2009","journal-title":"J Hepatol"},{"key":"R106-4-20210317","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0168-8278(01)00251-3","article-title":"Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment.","volume":"36","author":"Stiehl","year":"2002","journal-title":"J Hepatol"},{"key":"R107-4-20210317","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG clinical guideline: primary sclerosing cholangitis.","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R108-4-20210317","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/MCG.0b013e3181646713","article-title":"A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis.","volume":"42","author":"Gluck","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"R109-4-20210317","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0016-5107(01)70403-8","article-title":"Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis.","volume":"53","author":"Baluyut","year":"2001","journal-title":"Gastrointest Endosc"},{"key":"R110-4-20210317","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0039-6060(05)80078-9","article-title":"Primary sclerosing cholangitis: liver transplantation or biliary surgery.","volume":"117","author":"Farges","year":"1995","journal-title":"Surgery"},{"key":"R111-4-20210317","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/cncy.21331","article-title":"Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 199 predict risk of malignancy.","volume":"121","author":"Barr Fritcher","year":"2013","journal-title":"Cancer Cytopathol"},{"key":"R112-4-20210317","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1007\/s10620-005-2927-8","article-title":"The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis.","volume":"50","author":"Levy","year":"2005","journal-title":"Dig Dis Sci"},{"key":"R113-4-20210317","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/s10620-012-2401-3","article-title":"Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma.","volume":"58","author":"Venkatesh","year":"2013","journal-title":"Dig Dis Sci"},{"key":"R114-4-20210317","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1038\/ajg.2011.272","article-title":"Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma.","volume":"106","author":"Fritcher","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R115-4-20210317","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/ajg.2014.433","article-title":"Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis.","volume":"110","author":"Eaton","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R116-4-20210317","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Populationbased epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"key":"R117-4-20210317","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/hep.24570","article-title":"Cancer surveillance in patients with primary sclerosing cholangitis.","volume":"54","author":"Razumilava","year":"2011","journal-title":"Hepatology"},{"key":"R118-4-20210317","first-page":"e3","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers.","volume":"143","author":"Murad","year":"2012","journal-title":"Gastroenterology"},{"key":"R119-4-20210317","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hep.510300501","article-title":"Longterm results of patients undergoing liver transplantation for primary sclerosing cholangitis.","volume":"30","author":"Graziadei","year":"1999","journal-title":"Hepatology"},{"key":"R120-4-20210317","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/lt.21313","article-title":"Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course.","volume":"14","author":"Campsen","year":"2008","journal-title":"Liver Transplant"},{"key":"RU121-4-20210317","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Antigp210 and anticentromere antibodies are different risk factors for the progression of primary biliary cirrhosis.","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"key":"RU122-4-20210317","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0896-8411(03)00033-7","article-title":"Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study.","volume":"20","author":"Miyachi","year":"2003","journal-title":"J Autoimmun"},{"key":"RU123-4-20210317","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1440-1746.1998.01553.x","article-title":"S, ICHIDA T, YOSHIDA T et al. Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis.","volume":"13","year":"1998","journal-title":"J Gastroenterol Hepatol"},{"key":"RU124-4-20210317","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1542-3565(04)00465-3","article-title":"Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?","volume":"2","author":"Yang","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"RU125-4-20210317","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2009.08.009","article-title":"A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis.","volume":"34","author":"Agmon-Levin","year":"2010","journal-title":"J Autoimmun"},{"key":"RU126-4-20210317","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/liv.12690","article-title":"Antikelchlike 12 and antihexokinase 1: novel autoantibodies in primary biliary cirrhosis.","volume":"35","author":"Norman","year":"2015","journal-title":"Liver Int"}],"container-title":["Clinical and Translational Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ctg201533.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ctg201533","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/01720094-201508000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/ctg201533.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:10:24Z","timestamp":1786547424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01720094-201508000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":118,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1038\/ctg.2015.33","relation":{},"ISSN":["2155-384X"],"issn-type":[{"value":"2155-384X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}